Mammalian target of rapamycin complex 1, growth factors and hormones

Recent studies have established that mTORC1 activity critically affects food intake, body weight and peripheral metabolism⁽ Reference Cota, Proulx and Smith ^{6 –} Reference Ropelle, Pauli and Fernandes ^{8 )}.

To have such an impact, mTORC1 activity must be closely wired to the long-range communication signals that the body uses to coordinate the distribution of nutrients and the consequent tissue-specific functions relevant for the maintenance of energy balance.

Among those long-range communication signals, the hormones insulin and leptin play a central role⁽ Reference Morton, Cummings and Baskin ^{9 ,} Reference Schwartz, Woods and Porte ^{10 )}. They are known to act through the PI3 K/Akt pathway, which is among the intracellular cascades involved in determining the appetite-suppressing action of insulin and leptin in the hypothalamus⁽ Reference Plum, Belgardt and Bruning ^{11 ,} Reference Hill, Williams and Ye ^{12 )}.

Binding of insulin to its receptor leads to activation of both PI3 K and Akt, which inhibits tuberous sclerosis protein 2, a negative regulator of mTORC1⁽ Reference Inoki, Li and Zhu ^{13 )}. Interestingly, full activation of Akt requires mTORC2 activity, which is therefore posited upstream of mTORC1 and is relevant for mTORC1 functioning⁽ Reference Sarbassov, Guertin and Ali ^{14 )}.

However, growth factors can signal to mTORC1 through pathways other than the PI3 K/Akt cascade. For instance, evidence shows that growth factors can act onto mTORC1 through the extracellular signal regulated kinase 1/2, the Wnt pathway and the glycogen synthase kinase 3β⁽ Reference Ma, Chen and Erdjument-Bromage ^{15 ,} Reference Inoki, Ouyang and Zhu ^{16 )}.

Mammalian target of rapamycin complex 1 and cellular energy

mTORC1 senses levels of energy, namely ATP, available in the cell. This is relevant, taking into account that during states of cellular energy depletion and stress cells have to be readily capable to turn off anabolic and energy-consuming pathways such as the mTORC1 signalling. When the AMP:ATP ratio increases, the AMP-activated protein kinase (AMPK), a master sensor of intracellular fuel status⁽ Reference Hardie ^{17 )}, is activated and it inhibits mTORC1 by activating tuberous sclerosis protein 2⁽ Reference Inoki, Zhu and Guan ^{18 )} and inhibiting Raptor, a protein component of mTORC1⁽ Reference Gwinn, Shackelford and Egan ^{19 )}.

Consequently, mTORC1 activity is sensitive to any type of cellular stressor able to affect ATP levels, such as hypoxia, or stressors that critically affect cellular function, such as DNA damage (for review see⁽ Reference Zoncu, Efeyan and Sabatini ^{5 )}).

Mammalian target of rapamycin complex 1 and nutrients

mTORC1 signalling, as will be further detailed later, is a master regulator of protein synthesis and it is able to respond to the availability of amino acids, the building blocks of proteins. Amino acids are necessary to mTORC1 activity and their lack cannot be compensated for by other known mTORC1-activating stimuli⁽ Reference Hara, Yonezawa and Weng ^{20 )}. Among the amino acids, branched-chained amino acids (BCAA) and in particular leucine, which is a key activator of mTORC1, are transported and sensed intracellularly⁽ Reference Nicklin, Bergman and Zhang ^{21 )}. In turn, availability of amino acids increases intracellular calcium levels, thus activating mTORC1 through the involvement of a calcium/calmodulin-dependent activation of the class III PI3 K hVPS34⁽ Reference Gulati, Gaspers and Dann ^{22 ,} Reference Byfield, Murray and Backer ^{23 )}. Importantly, it has also been shown that amino acids, by recruiting the Rag family of small GTPases, cause mTORC1 to shuttle to lysosomes, allowing it to respond to growth factors and to eventually regulate cell autophagy (for review see⁽ Reference Zoncu, Efeyan and Sabatini ^{5 )}). However, the intracellular amino acid sensor that directly couples amino acid-dependent signalling to mTORC1 is not known. Recently, it has been proposed that such a role might be played by the leucyl-tRNA synthetase, an enzyme catalysing the ligation of leucine to its cognate transfer RNA, which has been shown to work as mTORC1-associated protein required for amino acid-induced mTORC1 activation⁽ Reference Han, Jeong and Park ^{24 )}.

Little is known on the intracellular mechanisms linking glucose availability to mTORC1 activation. Chemical inhibition of glycolysis suppresses mTORC1 activity⁽ Reference Dennis, Jaeschke and Saitoh ^{25 )} and low levels of glucose, by activating AMPK, also lead to mTORC1 inhibition. Conversely, mTORC1 promotes glucose uptake and flux through glycolysis, by activating the transcription and translation of the hypoxia-inducible factor 1α⁽ Reference Duvel, Yecies and Menon ^{26 )}.

Similarly, little is known on the mechanisms engaged by fatty acids to modulate mTORC1 activity, although it has been shown that dietary lipids phosphorylate activate the mTORC1 downstream target S6 kinase 1 (S6K1) in a muscle cell line independently of amino acids availability⁽ Reference Castaneda, Abplanalp and Um ^{27 )}. On the other hand, mTORC1 activity critically regulates lipid synthesis and adipocyte differentiation (see later).

Downstream of mammalian target of rapamycin complex 1: regulation of protein synthesis and beyond

mTORC1 regulates protein synthesis and translation by coordinating upstream inputs coming from growth factors, intracellular energy status and nutrient availability. In particular, mTORC1 phosphorylation of S6K1 and eukaryotic initiation factor 4E-binding proteins is the rate-limiting step for translation. S6K1 in turn phosphorylates a number of downstream substrates including the S6 ribosomal protein (S6) and leads to increased mRNA biogenesis and cap-dependent translation and elongation⁽ Reference Laplante and Sabatini ^{4 ,} Reference Howell and Manning ^{28 )}. The phosphorylation status of S6K1, S6 and 4E-binding proteins is often used as marker of mTORC1 activation in cells and tissues. And of relevance, in case of chronic activation of the pathway, S6K1 exerts an inhibitory role on insulin-dependent PI3 K/Akt activation through the inhibition of insulin receptor substrate proteins. Such negative feedback has been proposed to favour cellular insulin desensitisation and resistance⁽ Reference Um, Frigerio and Watanabe ^{29 )}.

Although mTORC1 stimulates protein synthesis, a process that requires high cellular energy levels, it also inhibits autophagy, a controlled self-degradation process, which provides energy substrates in times these are low (for review see⁽ Reference Zoncu, Efeyan and Sabatini ^{5 )}).

In addition, mTORC1 regulates several metabolic pathways through transcription. For instance, mTORC1 activity drives adipocyte differentiation and lipid accumulation by up-regulating the transcription factor PPARγ, probably through the activation of the sterol regulatory element-binding protein (SREBP). Conversely, rapamycin inhibits PPARγ and impairs adipocytes differentiation (for review see⁽ Reference Laplante and Sabatini ^{30 )}). The mTOR kinase also phosphorylates the signal transducer and activator of transcription 3, a transcription factor critically implicated in the actions of leptin on energy balance regulation⁽ Reference Bates, Stearns and Dundon ^{31 )}. Interestingly, mTOR-dependent phosphorylation of signal transducer and activator of transcription 3 leads to its translocation in the mitochondria, with consequent increase of oxidative phosphorylation⁽ Reference Wegrzyn, Potla and Chwae ^{32 )}. In fact, mTORC1 activity promotes mitochondria biogenesis and enhances mitochondrial respiration also by positively regulating the activity of the transcription factor PPARγ coactivator 1α⁽ Reference Cunningham, Rodgers and Arlow ^{33 )}. Accordingly, deletion of the mTORC1 protein Raptor in the muscle causes defective mitochondrial biogenesis and decreased oxidative capacity⁽ Reference Bentzinger, Romanino and Cloetta ^{34 )}.

Fig. 1 summarises the earlier-mentioned pathways involved in nutrient sensing and their relationship with mTORC1. For a more in-depth description of the molecular composition of mTORC1 and mTORC2 as well as of the growing number of intracellular pathways identified upstream and downstream of mTORC1, the reader should refer to recently published reviews focusing on these aspects⁽ Reference Zoncu, Efeyan and Sabatini ^{5 ,} Reference Howell and Manning ^{28 ,} Reference Laplante and Sabatini ^{35 )}.

Fig. 1. (colour online) The mammalian target of rapamycin complex 1 (mTORC1) pathway can be activated by hormones, growth factors and nutrients. Various upstream kinases [e.g. extracellular signal-regulated kinases1/2 (ERK1/2), phosphoinositide 3-kinase (PI3 K/Akt), AMP-activated protein kinase (AMPK)] that converge on the tuberous sclerosis complex (TSC1/TSC2), regulate mTORC1 activity. High-glucose levels inhibit AMPK, whereas low-glucose and low-ATP levels lead to the AMPK-dependent activation of TSC2, which inhibits mTORC1 signalling. AMPK also directly inhibits mTORC1 by phosphorylating Raptor, a component of mTORC1. Hormones such as insulin signal to mTORC1 through PI3 K and Akt, which inactivates TSC2 to prevent TSC2 inhibition of mTORC1. Activation of mTORC1 leads to phosphorylation of its downstream targets ribosomal protein S6 kinase (S6K1), eukaryotic initiation factor 4E-binding protein (4E-BP) and ribosomal protein S6 (S6). Prolonged or constitutive activation of mTORC1/S6K1 signalling attenuates insulin-dependent PI3 K/Akt activity by inhibiting insulin receptor substrate (IRS) proteins. Amino acids increase mTORC1 signalling by favouring Rag protein action on mTORC1 and its translocation to the lysosome, a phenomenon that leads to autophagy inhibition, and by inducing a Ca2⁺/calmodulin-mediated activation of the class III PI3 K human vacuolar protein sorting-34 (hVPS34). Certain fatty acids have been shown to activate mTORC1 downstream targets, but actual mechanisms of actions are currently unknown. Once activated the mTORC1 pathway affects the hypothalamic control of energy balance and regulates protein synthesis, whole body glucose metabolism, insulin sensitivity, lipogenesis and adipogenesis. BCAA, branched-chain amino acid.

Mammalian target of rapamycin complex 1 pathway and amino acids sensing

Within the last decade, the implication of the mTORC1 pathway in determining the anabolic effect of BCAA and leucine in particular has been extensively studied in skeletal muscle. Indeed, among the BCAA, leucine is the most effective in inducing protein synthesis in this tissue by stimulating the mTORC1 pathway⁽ Reference Proud ^{36 )}.

Several studies have also investigated BCAA and leucine ability to help preserve muscle mass and demonstrated their beneficial metabolic and clinical effects under different pathological conditions characterised by substantial loss of muscle, such as cancer and uraemia⁽ Reference Laviano, Muscaritoli and Cascino ^{37 )}. A lot of information is actually available on the safety and use of leucine as a supplement in the clinical setting, to help preserve muscle mass during wasting syndromes, as well as an anabolic enhancer consumed by athletes and body builders in the attempt to increase their muscle mass⁽ Reference Weitzel, Sandoval and Mayles ^{38 ,} Reference Greer, Woodard and White ^{39 )}. However, only very recent evidence has linked leucine and mTORC1 activity to energy balance regulation.

In 2006, we were the first to describe that leucine could acutely decrease food intake and body weight in lean rats when administered intracerebroventricularly within the brain⁽ Reference Cota, Proulx and Smith ^{6 )}. This effect was specific for leucine, since other BCAA such as valine did not affect food intake under the same conditions, and it was dependent on the activation of mTORC1 and its downstream targets S6K1 and S6 in the hypothalamus⁽ Reference Cota, Proulx and Smith ^{6 )}. The latter is one of the main brain structures involved in the regulation of energy balance⁽ Reference Morton, Cummings and Baskin ^{9 ,} Reference Shin, Zheng and Berthoud ^{40 )}.

Similar to leucine, the appetite-suppressant action of the adipocyte-derived hormone leptin, one of the major peripheral signals studied so far in the context of food intake and body weight regulation⁽ Reference Myers, Cowley and Munzberg ^{41 )}, depends on the activation of the hypothalamic mTORC1 signalling⁽ Reference Cota, Proulx and Smith ^{6 ,} Reference Cota, Matter and Woods ^{7 )}, thus suggesting that this pathway is an essential intracellular integrator of the actions of both nutrients and hormones on the central circuits regulating energy balance.

Other animal studies have subsequently described the appetite-suppressant action of leucine, by administering the amino acid either directly in the brain, or peripherally, as a dietary supplement. These reports further confirmed that leucine-induced decrease in food intake is dependent on hypothalamic mTORC1 activity and associated with the inhibition of AMPK⁽ Reference Ropelle, Pauli and Fernandes ^{8 ,} Reference Morrison, Xi and White ^{42 ,} Reference Blouet, Jo, Li and Schwartz ^{43 )}, an intracellular energy sensor known to inhibit mTORC1⁽ Reference Laplante and Sabatini ^{4 )}. Furthermore, intracerebroventricularly administration of leucine decreases gene expression levels of the appetite-inducing neuropeptides, Agouti-related protein and neuropeptide Y, while increasing mRNA levels of the appetite-suppressant precursor polypeptide pro-opio-melanocortin within the arcuate nucleus of the hypothalamus⁽ Reference Cota, Proulx and Smith ^{6 ,} Reference Ropelle, Pauli and Fernandes ^{8 ,} Reference Morrison, Xi and White ^{42 )}.

It has been further shown that the acute intra-hypothalamic administration of leucine or its metabolite alpha-ketoisocaproic acid in lean mice or rats reduces meal size and meal number by engaging a forebrain–hindbrain neurocircuit that activates pro-opio-melanocortin-producing neurons in the arcuate nucleus of the hypothalamus, oxytocin neurons in the paraventricular nucleus and satiety effector neurons in the brainstem⁽ Reference Blouet, Jo, Li and Schwartz ^{43 )}. Direct modulation of hypothalamic circuits by leucine might be physiologically relevant for the control of food intake, since levels of leucine in the cerebrospinal fluid are directly proportional to the level of the amino acid in the blood, which changes in relation to the quantity of leucine present in the meal⁽ Reference Blouet, Jo, Li and Schwartz ^{43 )}. Interestingly, published animal studies have shown that the administration of an increased amount of leucine directly through the diet can be equally feasible and efficient. In fact, a leucine-enriched standard diet is as effective in acutely reducing food intake in lean rats as a high-protein diet, when the leucine addition was equivalent to the amount of casein used in the high-protein diet⁽ Reference Ropelle, Pauli and Fernandes ^{8 )}.

Apart from its direct action on hypothalamic circuits, leucine might also modulate peripheral hormonal signals, which are in turn able to affect the activity of neurons controlling food intake and body weight. Indeed, it has been shown that the post-prandial rise of circulating leptin depends in part on the presence of leucine in the ingested food. Conversely, a leucine-deficient meal reduces by almost 40% the meal-related stimulation of leptin secretion in rats⁽ Reference Lynch, Gern and Lloyd ^{44 )}. Leucine-induced leptin secretion is associated to increased mTORC1 activity in the adipose tissue, which is actually required to increase plasma leptin, since administration of the mTOR inhibitor rapamycin inhibits the leptin peak⁽ Reference Lynch, Gern and Lloyd ^{44 )}. Thus, it is possible that part of the appetite-suppressant effect of leucine might depend on an increase in peripheral leptin levels and subsequent action of this hormone on neural circuits regulating food intake.

This set of initial observations has led to a series of intervention studies evaluating whether chronic leucine supplementation could be beneficial in models of diet-induced obesity.

Zhang and colleagues have reported that leucine supplementation (administered in water in sufficient quantity to double the circulating levels of the amino acid), reduces diet-induced body weight gain and adiposity in mice in a food-intake-independent manner, while improving both insulin sensitivity and dyslipidemia⁽ Reference Zhang, Guo and LeBlanc ^{45 )}. Weight-independent improvements in glycemic control after leucine supplementation were also described in a monogenic mouse model of obesity and in a polygenic model of type-2 diabetes⁽ Reference Guo, Yu and Hou ^{46 )}. Increased energy expenditure, associated to an improvement of mitochondrial oxidative function in the skeletal muscle and reduced inflammation in the white adipose tissue might explain the beneficial effects of leucine supplementation on body weight and glucose metabolism⁽ Reference Zhang, Guo and LeBlanc ^{45 –} Reference Macotela, Emanuelli and Bang ^{47 )}. These changes were also associated with an increase in mTORC1 activity in the liver, skeletal muscle and white fat⁽ Reference Macotela, Emanuelli and Bang ^{47 )}. However, not all studies have reported an effect on body weight⁽ Reference Macotela, Emanuelli and Bang ^{47 ,} Reference Nairizi, She and Vary ^{48 )} or relevant improvement in glucose metabolism⁽ Reference Nairizi, She and Vary ^{48 )}. Nevertheless, and in agreement with the suggested beneficial role of higher leucine levels on the regulation of adiposity, mice lacking the mitochondrial branched-chain aminotransferase, which catalyses the first step of BCAA metabolism, have elevated plasma BCAA, decreased adiposity and body weight, improved insulin sensitivity and increased energy expenditure, which results from futile cycles due to increased protein degradation and synthesis associated with increased mTORC1 activity in skeletal muscle⁽ Reference She, Reid and Bronson ^{49 )}. Accordingly, a recent cross-sectional epidemiological investigation has reported that a higher BCAA intake is actually associated with a lower prevalence of overweight and obesity in otherwise healthy middle-aged adults⁽ Reference Qin, Xun and Bujnowski ^{50 )}.

Whilst it must also be mentioned that recent studies in human subjects have linked high circulating levels of BCAA to insulin resistance and diabetes⁽ Reference Newgard, An and Bain ^{51 ,} Reference Wang, Larson and Vasan ^{52 )}, it is unclear from these studies whether elevated BCAA levels are the cause or consequence of the observed metabolic phenotypes.

Finally, BCAA supplementation has been shown to increase the lifespan in mice⁽ Reference D'Antona, Ragni and Cardile ^{53 )}. This effect was associated with an increase in mitochondrial biogenesis in muscle, through increased endothelial nitric oxide synthase and mTORC1 activity, which favoured increased physical endurance⁽ Reference D'Antona, Ragni and Cardile ^{53 )}. Seemingly in contrast to these findings, other studies have reported that reduced mTORC1 signalling underlies life span extension by energy restriction, since both chronic rapamycin administration and S6K1 deletion increase life span, an effect observed prevalently or only in female mice⁽ Reference Selman, Tullet and Wieser ^{54 ,} Reference Harrison, Strong and Sharp ^{55 )}. Thus, the apparent divergent evidence available so far overall suggests that the role of mTORC1 signalling in energy restriction and lifespan modulation might be more complex than what was initially thought, and likely tissue-specific.

Mammalian target of rapamycin complex 1 pathway and glucose sensing

Like amino acids, glucose is also able to activate the mTORC1 pathway in cells and its action on this signalling cascade as well as the relationship between mTORC1 activity and glucose uptake and metabolism have been mostly studied in the skeletal muscle and endocrine pancreas. It is known, for instance, that in vitro exposure to 2-deoxiglucose, a non-metabolisable glucose analogue, which impedes glucose utilisation, rapidly inhibits mTORC1 signalling⁽ Reference Dennis, Jaeschke and Saitoh ^{25 )}. Conversely, rapamycin-mediated inhibition of mTORC1 activity in muscle cells reduces glucose utilisation while increasing fatty acid oxidation⁽ Reference Sipula, Brown and Perdomo ^{56 )}, thus suggesting that mTORC1 activity determines fuel substrate use. Instead, high glucose levels in vitro favour intracellular lipid accumulation and adipogenesis through the mTORC1-dependent activation of SREBP (for review see⁽ Reference Laplante and Sabatini ^{30 ,} Reference Yue, Yin and Li ^{57 )}).

Glucose also has a permissive role in promoting insulin-dependent regulation of mTORC1 targets, such as 4E-binding proteins 1⁽ Reference Patel, Wang and Proud ^{58 )}, whereas mTORC1 activity leads to increased expression of glucose transporters in several cell types, thus further favouring glucose uptake⁽ Reference Buller, Loberg and Fan ^{59 )}.

In pancreatic islets, glucose requires a functional mTORC1 signalling to enhance β-cell growth and proliferation⁽ Reference McDaniel, Marshall and Pappan ^{60 )}, a phenomenon relevant for the appropriate, compensatory response of the islets to chronic nutrient overload and increased insulin demand during type-2 diabetes. In fact, it has been shown that rapamycin administration inhibits β-cell proliferation, induces β-cell apoptosis and causes fulminant diabetes in obese animal models⁽ Reference Fraenkel, Ketzinel-Gilad and Ariav ^{61 ,} Reference Zahr, Molano and Pileggi ^{62 )}. Although genetic models with specific overactivity of mTORC1 in β cells, due to deletion of tuberous sclerosis protein 2 (an inhibitor of mTORC1) or liver kinase B1 (an activator of AMPK), have increased β-cell mass and improved glucose tolerance⁽ Reference Rachdi, Balcazar and Osorio-Duque ^{63 ,} Reference Fu, Ng and Depatie ^{64 )}.

Less explored is the relationship between glucose sensing and mTORC1 signalling in the hypothalamic regulation of energy balance. However, a recently published study has shown that hypothalamic mTORC1 activation by glucose mediates activation of hypoxia-inducible factor, which in turn regulates glucose-dependent food intake and body weight by increasing expression of the anorexigenic pro-opio-melanocortin peptide⁽ Reference Zhang, Zhang and Gonzalez ^{65 )}. Genetic deletion of hypoxia-inducible factor in pro-opio-melanocortin neurons, which are glucose responsive and are known to regulate whole-body glucose homoeostasis⁽ Reference Parton, Ye and Coppari ^{66 )}, impairs hypothalamic glucose sensing and favours the development of obesity, while overexpression of hypoxia-inducible factor in the mediobasal hypothalamus decreases body weight gain during exposure to a high-fat diet, mainly by reducing food intake in treated mice⁽ Reference Zhang, Zhang and Gonzalez ^{65 )}.

Mammalian target of rapamycin complex 1 pathway and fatty acids sensing

As previously mentioned, very little is known on the ability of lipids to activate the mTORC1 pathway in cells. Although, both oleic and palmitoleic acid drive phosphorylation of S6K1 in muscle cells independently of amino acid availability⁽ Reference Castaneda, Abplanalp and Um ^{27 )}. Moreover, palmitate exposure increases insulin-stimulated S6K1 phosphorylation in L6 myotubes, while AMPK activation abolishes lipid-induced mTORC1 activation⁽ Reference Rivas, Yaspelkis and Hawley ^{67 )}. Consequently, excess of fatty acids drives insulin resistance in vitro in hepatocytes and muscle cells through overstimulation of mTORC1 signalling⁽ Reference Mordier and Iynedjian ^{68 ,} Reference Wang, Yu and Nawaz ^{69 )}.

On the other hand, studies published over the past few years show that mTORC1 signalling is a critical regulator of lipid biosynthesis, an essential mechanism guaranteeing the production of lipids then used by the cells to constitute membranes, as precursors of other cellular constituents or as signalling molecules (for review see⁽ Reference Laplante and Sabatini ^{30 )}). Insulin treatment or constitutive Akt activation rapidly induces nuclear accumulation of SREBP-1 and the expression of lipogenic genes, such as acetyl-CoA carboxylase, fatty acid synthase (FAS) and stearoyl-CoA desaturase 1. mTORC1 activity is required for SREBP-1 recruitment [reviewed in⁽ Reference Laplante and Sabatini ^{30 )}]. Dysregulation of such mechanism due to mTORC1 overactivity might favour the development of non-alcoholic fatty liver disease, the most common liver disease found in obesity and type-2 diabetes (for review see⁽ Reference Laplante and Sabatini ^{30 )}). mTORC1 activity also induces adipogenesis in the adipose tissue through the activation of PPARγ, its co-activator lipin1 and SREBP-1 (for review see⁽ Reference Laplante and Sabatini ^{30 )}).

Interestingly, mice lacking S6K1 and therefore characterised by a defective mTORC1 signalling, have reduced adipose tissue mass and are resistant to diet-induced obesity⁽ Reference Um, Frigerio and Watanabe ^{29 )}. This seems due to the fact that S6K1 is required for the commitment of embryonic stem cells to adipocyte progenitors, while being dispensable for terminal adipocyte differentiation⁽ Reference Carnevalli, Masuda and Frigerio ^{70 )}.

Exposure to high-saturated fat diets results in a resistance to the actions of both leptin and insulin at the level of the hypothalamus (for review see⁽ Reference Cota, Proulx and Seeley ^{71 )}). However, the role of fatty acid metabolism in the hypothalamic regulation of energy balance, and its reciprocal relationship with glucose metabolism has only recently begun to be investigated.

Neurons derive most of their ATP from the oxidation of glucose rather than lipids⁽ Reference Sokoloff ^{72 )}. Nevertheless, the use of FAS inhibitors and of other pharmacological or genetic tools able to modulate different enzymes of the FAS pathway in the hypothalamus suggests that this pathway integrates signals from nutrients and nutrient-derived hormones and therefore affects energy balance regulation⁽ Reference Loftus, Jaworsky and Frehywot ^{73 –} Reference Wortman, Clegg and D'Alessio ^{75 )}.

In the hypothalamus, AMPK inhibits fatty acid synthesis by inhibiting acetyl-CoA carboxylase, the enzyme controlling the conversion of acetyl-CoA to malonyl-CoA, an intermediate of fatty acid synthesis, which is considered to work as a fuel-sensing signal⁽ Reference Loftus, Jaworsky and Frehywot ^{73 ,} Reference Lam, Schwartz and Rossetti ^{74 )}. The gastric hormone ghrelin increases food intake by driving hypothalamic AMPK activity and consequently increasing fatty acid oxidation in this brain area⁽ Reference Lopez, Lage and Saha ^{76 )}. Conversely, leptin decreases food intake by inhibiting AMPK activity⁽ Reference Minokoshi, Alquier and Furukawa ^{77 )}, and increasing hypothalamic acetyl-CoA carboxylase activity and malonyl-CoA levels⁽ Reference Gao, Kinzig and Aja ^{78 )}.

In addition, we have recently shown that intracerebroventricular administration of inhibitors of the FAS pathway decrease food intake via an mTORC1-dependent mechanism⁽ Reference Proulx, Cota and Woods ^{79 )}. FAS inhibitors possibly suppress food ingestion by increasing hypothalamic glucose utilisation⁽ Reference Wortman, Clegg and D'Alessio ^{75 )}. Thus, during ketosis, when neurons use ketone bodies in preference to glucose, central administration of FAS inhibitors has no effect on food intake or hypothalamic mTORC1 activity⁽ Reference Wortman, Clegg and D'Alessio ^{75 ,} Reference Proulx, Cota and Woods ^{79 )}. This therefore suggests that a regulatory loop exists between fatty acid metabolism and mTORC1 signalling, such that inhibition of FAS drives mTORC1 activity depending on glucose availability and/or utilisation⁽ Reference Proulx, Cota and Woods ^{79 )}.